Antitubercular therapy-induced psychosis

Bhanudeep Singanamala, MD, Lokesh Saini, DM, Priyanka Madaan, DM, Paramjeet Singh, MD, Pankaj C. Vaidya, MD, and Jitendra Kumar Sahu, DM

Neurology® 2019;93:1012-1013. doi:10.1212/WNL.00000000000008578

Correspondence

Dr. Saini
drlokeshsaini@gmail.com

Figure 1 Brain MRI of the index patient at the time of presentation

Brain MRI (T2-weighted [A, B], diffusion-weighted [C, D], and apparent diffusion coefficient images [E, F]) reveals T2-hyperintense thalami and dentate nuclei along with diffusion restriction in bilateral thalami and vasogenic edema in the dentate nuclei (C, F). These radiologic findings are consistent with cycloserine toxicity in the described clinical setting.

A 12-year-old girl with multidrug-resistant pulmonary tuberculosis presented with a 5-day history of headache and psychosis; at the time, she was taking a complex antitubercular therapy (ATT; kanamycin, levofloxacin, ethionamide, pyrazinamide, cycloserine, ethambutol) and pyridoxine. Examination revealed fluctuating sensorium and aggression. The differentials included neurotuberculosis, immune-reconstitution-inflammatory syndrome, and drug-induced psychosis. Neuroimaging revealed features of cycloserine-induced encephalopathy (CIE; figure 1, A–F). Cycloserine was replaced with linezolid and there was a complete resolution of the clinicroadiologic presentation over 4 weeks (figure 2, A–D), confirming the diagnosis.

Cycloserine, an NMDA partial agonist, is widely used in ATT regimens. It can cause reversible encephalopathy.¹ Clinicians should be aware of CIE when considering treatment options.

Acknowledgment

The authors thank the parents of the patient for the images.

Study funding

No targeted funding reported.

From the Pediatric Neurology Unit, Department of Pediatrics, Advanced Pediatrics Centre (B.S., L.S., P.M., P.C.V., J.K.S.), and Department of Radiodiagnosis (P.S.), Post Graduate Institute of Medical Education & Research, Chandigarh; and Council of Scientific and Industrial Research (P.M.), New Delhi, India.

Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Figure 2 Follow-up brain MRI 4 weeks after stopping cycloserine

Repeat brain MRI 4 weeks later (T2-weighted [A, B] and apparent diffusion coefficient images [C, D]) reveal the complete resolution of thalamic and dentate signal changes and diffusion abnormalities.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Appendix Authors

Name	Location	Role	Contribution
Bhanudeep Singanamala, MD	PGIMER, Chandigarh, India	Author	Patient management, literature review, initial draft manuscript preparation
Lokesh Saini, MD, DM	PGIMER, Chandigarh, India	Author	Concept and design of the study, analysis of the radiologic data, critical review of the manuscript, final approval of the version to be published
Priyanka Madaan, MD, DM	PGIMER, Chandigarh, India	Author	Patient management, literature review, initial draft manuscript preparation

Appendix (continued)

Name	Location	Role	Contribution
Paramjeet Singh, MD	PGIMER, Chandigarh, India	Author	Analysis of the radiologic data, critical review of manuscript, final approval of the version to be published
Pankaj C. Vaidya, MD	PGIMER, Chandigarh, India	Author	Patient management, critical review of manuscript, final approval of the version to be published
Jitendra Kumar Sahu, MD, DM	PGIMER, Chandigarh, India	Author	Patient management, critical review of manuscript for important intellectual content, final approval of the version to be published

Reference

1. Kim S, Kang M, Cho JH, Choi S. Reversible magnetic resonance imaging findings in cycloserine-induced encephalopathy: a case report. *Neurol Asia* 2014;19:417–419.

Practice Current: An interactive exchange on controversial topics

Share your own best practices.
Read commentary with expert opinion.
Explore results on an interactive world map.

NPub.org/NCP/practicecurrent

Neurology® Clinical Practice

Neurology®

Antitubercular therapy-induced psychosis

Bhanudeep Singanamala, Lokesh Saini, Priyanka Madaan, et al.

Neurology 2019;93;1012-1013

DOI 10.1212/WNL.00000000000008578

This information is current as of December 2, 2019

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/93/23/1012.full
References	This article cites 1 articles, 0 of which you can access for free at: http://n.neurology.org/content/93/23/1012.full#ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): Bacterial infections http://n.neurology.org/cgi/collection/bacterial_infections MRI http://n.neurology.org/cgi/collection/mri
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2019 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.